Chart-Typ:
Zeitraum:
| PESG Research: PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch | With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could... ► Artikel lesen |
| wO Börsenlounge: Palantir | Apple | Adidas & Summit Therapeutics sticht Merck & Co aus | 2023 erzielte Merck & Co. mit dem Krebsmedikament Keytruda einen Umsatz von rund 25 Milliarden $. Jetzt sagt Summit, dass sein neues Medikament eine signifikante Verbesserung bietet. Ist Mercks Blockbuster... ► Artikel lesen |
| Summit Therapeutics Inc.: Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China | Summit to Initiate HARMONi-7, a Phase III Trial in First-Line PD-L1 High, Advanced NSCLC, in Early 2025 Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab... ► Artikel lesen |
| Zenas BioPharma Announces Pricing of Upsized Initial Public Offering | WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen |
| Zenas BioPharma Prices 11.76 Mln IPO At $16 - $18/share | WASHINGTON (dpa-AFX) - Zenas BioPharma, Inc. announced on Friday its intention to offer 11.76 million shares priced between $16 and $18 each for its Initial Public Offering. The company has... ► Artikel lesen |
| Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer | Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical productsWALTHAM... ► Artikel lesen |
| MBX Biosciences Prices IPO Of 10.20 Mln Shares At $16.00/shr | WASHINGTON (dpa-AFX) - MBX Biosciences Inc. (MBX) said that it has priced its initial public offering of 10.20 million shares of its common stock at $16.00 per share.The company noted that it... ► Artikel lesen |
| MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Initial Public Offering | CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) ("MBX Biosciences"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel... ► Artikel lesen |
| MBX Biosciences Offers 8.5 Mln IPO At $14-$16/share | WASHINGTON (dpa-AFX) - Monday, MBX Biosciences, a biotech firm focused on developing therapies for rare endocrine diseases, announced the initial public offering of 8.5 million shares, with... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACE ONCOLOGY LTD finden Sie auf Wallstreet Online.
